IQVIA And Medera Partner To Advance Cardiac Gene Therapy And Human-Based Drug Discovery

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic collaboration with clinical-stage biopharmaceutical company Medera Inc. to accelerate the development of innovative cardiac gene therapies and human-based drug discovery platforms. The partnership aims to combine the strengths of both companies to support the development of new treatments for cardiovascular diseases.

The collaboration brings together IQVIA's global expertise in clinical trial management, regulatory support, and commercialization with Medera's two specialized platforms. These include Sardocor, which focuses on developing disease-modifying gene therapies for difficult-to-treat cardiovascular conditions, and Novoheart, which develops engineered human cardiac tissue models for disease research, drug discovery, and safety testing.

As part of the agreement, Sardocor will utilize IQVIA's experience in clinical trial execution and regulatory strategy to advance its FDA-cleared, first-in-human adeno-associated virus (AAV)-based gene therapy programs. IQVIA will support key areas such as patient recruitment, clinical data management, regulatory submissions, and applications for expedited FDA designations to help accelerate development.

Novoheart's mini-Heart platform, which uses engineered human heart tissue to study diseases and evaluate new therapies, has already contributed to securing Investigational New Drug (IND) and FDA Fast Track designations. The platform provides a human-based alternative to traditional animal testing and is being expanded to include multiple organ systems to support broader drug discovery and safety assessment in line with the FDA Modernization Act 2.0.

Ronald Li, Co-Founder, Chairman and Chief Executive Officer of Medera, said the collaboration combines IQVIA's global clinical expertise with Medera's advanced gene therapy and human tissue technologies to accelerate the delivery of safer and more effective treatments for patients. He added that the partnership strengthens the company's scientific and regulatory progress while expanding the adoption of human-based drug discovery and next-generation cardiac gene therapies.

Through this collaboration, both companies aim to accelerate innovation in cardiovascular medicine by improving the efficiency of clinical development, advancing gene therapy programs, and promoting more predictive human-based research models that could enhance future drug development and patient outcomes.